Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: A Children's Oncology Group phase I consortium report

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 316-323

  Berg, Stacey L ^a   Cairo, Mitchell S ^a   Russell, Heidi ^a   Ayello, Janet ^a   Ingle, Ashish Mark ^a   Lau, Henry ^a   Chen, Nianhang ^a   Adamson, Peter C ^a   Blaney, Susan M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; LENALIDOMIDE;

ADOLESCENT; ADULT; ARTICLE; BRAIN ISCHEMIA; CANCER RELAPSE; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CYTOTOXICITY; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; IMMUNOMODULATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SOMNOLENCE; TREATMENT OUTCOME; URTICARIA;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNITY, CELLULAR; INFANT; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; RECURRENCE; SALVAGE THERAPY; THALIDOMIDE; YOUNG ADULT;

EID: 79951977934     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.8387     Document Type: Article

References (54)

1. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol 39:1489-1499, 2007 (Pubitemid 47031027)
2. Dredge K, Horsfall R, Robinson SP, et al: Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56-63, 2005 (Pubitemid 40410468)
3. Dredge K, Marriott JB, Macdonald CD, et al: Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87:1166-1172, 2002 (Pubitemid 35418112)
4. Corral LG, Haslett PA, Muller GW, et al: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380-386, 1999 (Pubitemid 29295864)
5. Payvandi F, Wu L, Haley M, et al: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230:81-88, 2004
6. Haslett PA, Corral LG, Albert M, et al: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885-1892, 1998
7. Marriott JB, Clarke IA, Dredge K, et al: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130:75-84, 2002
8. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al: Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11:5984-5992, 2005 (Pubitemid 41170330)
9. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 140:36-45, 2008 (Pubitemid 350233246)
10. Tai YT, Li XF, Catley L, et al: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: Clinical implications. Cancer Res 65:11712-11720, 2005 (Pubitemid 41821732)
11. Wu L, Adams M, Carter T, et al: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 14:4650-4657, 2008
12. Zhu D, Corral LG, Fleming YW, et al: Immunomodulatory drugs Revlimid((R)) (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57:1849-1859, 2008
13. Nguyen M, Tran C, Barsky S, et al: Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies. Int J Oncol 10:965-969, 1997 (Pubitemid 27210163)
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
16. Chen N, Lau H, Kong L, et al: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475, 2007 (Pubitemid 350115306)
17. Ayello J, van de Ven C, Cairo E, et al: Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy. Exp Hematol 37:1216-1229, 2009
18. Chang DH, Liu N, Klimek V, et al: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 108:618-621, 2006 (Pubitemid 44061362)
19. Alter G, Malenfant JM, Altfeld M: CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15-22, 2004 (Pubitemid 39626587)
20. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low- and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
21. Richardson PG, Schlossman RL, Weller E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067, 2002 (Pubitemid 35217050)
22. Warren K, Goldman S, Stewart C, et al: Phase I trial of CC-5013 (lenalidomide) in pediatric patients with recurrent of refractory primary CNS tumors. Neuro-Oncology 10:835-836, 2008
23. Menon SP, Rajkumar SV, Lacy M, et al: Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer 112:1522-1528, 2008 (Pubitemid 351441164)
24. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 25:4459-4465, 2007 (Pubitemid 350063804)
25. Palumbo A, Rajkumar SV, Dimopoulos MA, et al: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423, 2008 (Pubitemid 351255436)
26. Andritsos LA, Johnson AJ, Lozanski G, et al: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26:2519-2525, 2008
27. Chanan-Khan AA, Whitworth A, Bangia N, et al: Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 26:4851-4852, 2008
28. Fine HA, Kim L, Albert PS, et al: A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res 13:7101-7106, 2007 (Pubitemid 350276894)
29. Dahut WL, Aragon-Ching JB, Woo S, et al: Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49:650-660, 2009
30. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005 (Pubitemid 40204668)
31. Amato RJ, Hernandez-McClain J, Saxena S, et al: Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31:244-249, 2008
32. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006 (Pubitemid 46623164)
33. Choueiri TK, Dreicer R, Rini BI, et al: Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107:2609-2616, 2006 (Pubitemid 44845615)
34. Miller AA, Case D, Harmon M, et al: Phase I study of lenalidomide in solid tumors. J Thorac Oncol 2:445-449, 2007 (Pubitemid 47181700)
35. Zhang MM, Chan JK, Husain A, et al: Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma. Gynecol Oncol 105:194-198, 2007 (Pubitemid 46441459)
36. Sharma RA, Steward WP, Daines CA, et al: Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42:2318-2325, 2006 (Pubitemid 44307625)
37. Bartlett JB, Michael A, Clarke IA, et al: Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90:955-961, 2004 (Pubitemid 38495811)
38. Schey SA, Fields P, Bartlett JB, et al: Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22:3269-3276, 2004 (Pubitemid 41103682)
39. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
40. Hayashi T, Hideshima T, Akiyama M, et al: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: Clinical application. Br J Haematol 128:192-203, 2005
41. Carson WE, Giri JG, Lindemann MJ, et al: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180:1395-1403, 1994 (Pubitemid 24289613)
42. Decot V, Voillard L, Latger-Cannard V, et al: Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: Comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol 38:351-362, 2010
43. Kennedy MK, Glaccum M, Brown SN, et al: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771-780, 2000
44. Armitage JO: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92:4491-4508, 1998
45. Farag SS, Caligiuri MA: Human natural killer cell development and biology. Blood Rev 20:123-137, 2006 (Pubitemid 43786166)
46. Lieberman J: The AB: Cs of granule-mediated cytotoxicity: New weapons in the arsenal. Nat Rev Immunol 3:361-370, 2003
47. Galustian C, Meyer B, Labarthe MC, et al: The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58:1033-1045, 2009
48. Nizar S, Copier J, Meyer B, et al: T-regulatory cell modulation: The future of cancer immunotherapy? Br J Cancer 100:1697-1703, 2009
49. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004 (Pubitemid 39273735)
50. Diederichsen AC, Zeuthen J, Christensen PB, et al: Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer 35:721-726, 1999 (Pubitemid 29258140)
51. Beyer M, Kochanek M, Giese T, et al: In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107:3940-3949, 2006
52. Yang ZZ, Novak AJ, Stenson MJ, et al: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006
53. Motta M, Rassenti L, Shelvin BJ, et al: Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19:1788-1793, 2005 (Pubitemid 41486157)
54. Chauhan D, Singh AV, Ciccarelli B, et al: Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115:834-845, 2010